2C-D: Difference between revisions

Line 5:

The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences.<ref>Amphetamine analogs. II. Methylated phenethylamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/5412084</ref> Initial trials by [[Alexander Shulgin]] at sub-threshold doses in humans were carried out in 1964.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p94, p175 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf</ref>

In his book [[PiHKAL]] ("Phenethylamines I Have Known And Loved"), Shulgin lists the dosage range as being from 20 to 60 mg. This is now regarded by some as a conservative estimate as it has since been reported that substantially higher doses are capable of inducing a full spectrum of classical psychedelic effects while remaining physically unthreatening, a relatively unique quality in the [[2C-x family]].

Many anecdotal reports suggest that it is calmer, easier to handle and more comfortable on the body than other closely related [[psychedelic]] [[phenethylamines]]. While not especially visual or physically euphoric at common doses, it is reported to be very lucid, analytical and unimpaired in its headspace - a quality it retains even as the dose is increased.

Line 31:

Line 29:

==Subjective effects==

In his book [[PiHKAL]] ("Phenethylamines I Have Known And Loved"), Shulgin lists the dosage range as being from 20 to 60 mg. This is now regarded by some as a conservative estimate as it has since been reported that substantially higher doses are capable of inducing a full spectrum of classical psychedelic effects while remaining physically unthreatening, a relatively unique quality in the [[2C-x family]].

{{effects/base

@@ Line 5: / Line 5: @@
 The synthesis of 2C-D was first published in 1970 by a team from the Texas Research Institute of Mental Sciences.<ref>Amphetamine analogs. II. Methylated phenethylamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/5412084</ref> Initial trials by [[Alexander Shulgin]] at sub-threshold doses in humans were carried out in 1964.<ref>Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p94, p175 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf</ref>
-In his book [[PiHKAL]] ("Phenethylamines I Have Known And Loved"), Shulgin lists the dosage range as being from 20 to 60 mg. This is now regarded by some as a conservative estimate as it has since been reported that substantially higher doses are capable of inducing a full spectrum of classical psychedelic effects while remaining physically unthreatening, a relatively unique quality in the [[2C-x family]].
 Many anecdotal reports suggest that it is calmer, easier to handle and more comfortable on the body than other closely related [[psychedelic]] [[phenethylamines]]. While not especially visual or physically euphoric at common doses, it is reported to be very lucid, analytical and unimpaired in its headspace - a quality it retains even as the dose is increased.
@@ Line 31: / Line 29: @@
 ==Subjective effects==
+In his book [[PiHKAL]] ("Phenethylamines I Have Known And Loved"), Shulgin lists the dosage range as being from 20 to 60 mg. This is now regarded by some as a conservative estimate as it has since been reported that substantially higher doses are capable of inducing a full spectrum of classical psychedelic effects while remaining physically unthreatening, a relatively unique quality in the [[2C-x family]].
 {{Preamble/SubjectiveEffects}}
 {{effects/base